

Andrew D Simmons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/514374/publications.pdf>

Version: 2024-02-01

23
papers

2,054
citations

840776

11
h-index

752698

20
g-index

23
all docs

23
docs citations

23
times ranked

3806
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	12.8	520
2	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	1.6	448
3	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	9.4	310
4	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	7.0	273
5	Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. <i>Nature Medicine</i> , 2019, 25, 111-118.	30.7	196
6	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	7.0	101
7	Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3651-3667.	6.4	57
8	Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. <i>BMC Cancer</i> , 2020, 20, 215.	2.6	30
9	Evaluation of <i>in vitro</i> absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. <i>Xenobiotica</i> , 2020, 50, 1032-1042.	1.1	25
10	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.	3.0	22
11	TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS389-TPS389.	1.6	17
12	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	7.0	12
13	TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS388-TPS388.	1.6	11
14	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	1.4	7
15	Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1) Tj ETQq1 1 0.784314 rgBT /Overl... <i>Oncology</i> , 2019, 37, 5019-5019.	1.6	7
16	Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 671-682.	2.3	7
17	Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5031-5031.	1.6	4
18	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 25-25.	1.6	2

#	ARTICLE	IF	CITATIONS
19	ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, TPS496-TPS496.	1.6	2
20	Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. Journal of Clinical Oncology, 2017, 35, TPS5087-TPS5087.	1.6	2
21	ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2018, 36, TPS4592-TPS4592.	1.6	1
22	Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2018, 36, 447-447.	1.6	0
23	Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.. Journal of Clinical Oncology, 2018, 36, 5582-5582.	1.6	0